These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 36344940)
1. The effect of N-acetylcysteine in patients with non-cystic fibrosis bronchiectasis (NINCFB): study protocol for a multicentre, double-blind, randomised, placebo-controlled trial. Liao Y; Wu Y; Zi K; Shen Y; Wang T; Qin J; Chen L; Chen M; Liu L; Li W; Zhou H; Xiong S; Wen F; Chen J BMC Pulm Med; 2022 Nov; 22(1):401. PubMed ID: 36344940 [TBL] [Abstract][Full Text] [Related]
2. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis. Aksamit T; Bandel TJ; Criollo M; De Soyza A; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R Contemp Clin Trials; 2017 Jul; 58():78-85. PubMed ID: 28495619 [TBL] [Abstract][Full Text] [Related]
3. Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials. Paredes Aller S; Quittner AL; Salathe MA; Schmid A Expert Rev Respir Med; 2018 Sep; 12(9):769-782. PubMed ID: 30025482 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study. Jayaram L; King PT; Hunt J; Lim M; Park C; Hu E; Dousha L; Ha P; Bartlett JB; Southcott AM; Muruganandan S; Vogrin S; Rees MA; Dean OM; Wong CA Pulm Pharmacol Ther; 2024 Mar; 84():102283. PubMed ID: 38141851 [TBL] [Abstract][Full Text] [Related]
5. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B; Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664 [TBL] [Abstract][Full Text] [Related]
6. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Wong C; Jayaram L; Karalus N; Eaton T; Tong C; Hockey H; Milne D; Fergusson W; Tuffery C; Sexton P; Storey L; Ashton T Lancet; 2012 Aug; 380(9842):660-7. PubMed ID: 22901887 [TBL] [Abstract][Full Text] [Related]
7. Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial. Chang AB; Grimwood K; Robertson CF; Wilson AC; van Asperen PP; O'Grady KA; Sloots TP; Torzillo PJ; Bailey EJ; McCallum GB; Masters IB; Byrnes CA; Chatfield MD; Buntain HM; Mackay IM; Morris PS Trials; 2012 Aug; 13():156. PubMed ID: 22937736 [TBL] [Abstract][Full Text] [Related]
8. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Valery PC; Morris PS; Byrnes CA; Grimwood K; Torzillo PJ; Bauert PA; Masters IB; Diaz A; McCallum GB; Mobberley C; Tjhung I; Hare KM; Ware RS; Chang AB Lancet Respir Med; 2013 Oct; 1(8):610-620. PubMed ID: 24461664 [TBL] [Abstract][Full Text] [Related]
9. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China. Tian H; Zhou Y; Tang L; Wu F; Deng Z; Lin B; Huang P; Wei S; Zhao D; Zheng J; Zhong N; Ran P Trials; 2020 Sep; 21(1):780. PubMed ID: 32917271 [TBL] [Abstract][Full Text] [Related]
10. Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis. Chorepsima S; Kechagias KS; Kalimeris G; Triarides NA; Falagas ME Drug Des Devel Ther; 2018; 12():4059-4066. PubMed ID: 30568427 [TBL] [Abstract][Full Text] [Related]
11. Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial. Chang AB; Grimwood K; Wilson AC; van Asperen PP; Byrnes CA; O'Grady KA; Sloots TP; Robertson CF; Torzillo PJ; McCallum GB; Masters IB; Buntain HM; Mackay IM; Ungerer J; Tuppin J; Morris PS Trials; 2013 Feb; 14():53. PubMed ID: 23421781 [TBL] [Abstract][Full Text] [Related]
12. To investigate the prevention of OM-85 on bronchiectasis exacerbations (iPROBE) in Chinese patients: study protocol for a randomized controlled trial. Gao J; Gao X; Kong L Trials; 2014 Apr; 15():150. PubMed ID: 24773830 [TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Laska IF; Crichton ML; Shoemark A; Chalmers JD Lancet Respir Med; 2019 Oct; 7(10):855-869. PubMed ID: 31405826 [TBL] [Abstract][Full Text] [Related]
14. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914 [TBL] [Abstract][Full Text] [Related]
15. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Barker AF; O'Donnell AE; Flume P; Thompson PJ; Ruzi JD; de Gracia J; Boersma WG; De Soyza A; Shao L; Zhang J; Haas L; Lewis SA; Leitzinger S; Montgomery AB; McKevitt MT; Gossage D; Quittner AL; O'Riordan TG Lancet Respir Med; 2014 Sep; 2(9):738-49. PubMed ID: 25154045 [TBL] [Abstract][Full Text] [Related]
16. A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol. Maier A; Dharan A; Oliver G; Berk M; Redston S; Back SE; Kalivas P; Ng C; Kanaan RA BMC Psychiatry; 2020 Aug; 20(1):397. PubMed ID: 32762663 [TBL] [Abstract][Full Text] [Related]
17. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Chalmers JD; Boersma W; Lonergan M; Jayaram L; Crichton ML; Karalus N; Taylor SL; Martin ML; Burr LD; Wong C; Altenburg J Lancet Respir Med; 2019 Oct; 7(10):845-854. PubMed ID: 31405828 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of Luo A; Liu X; Hu Q; Yang M; Jiang H; Liu W BMJ Open; 2022 Mar; 12(3):e053625. PubMed ID: 35361640 [TBL] [Abstract][Full Text] [Related]
19. Daily versus three-times-weekly azithromycin in Chinese patients with non-cystic fibrosis bronchiectasis: protocol for a prospective, open-label and randomised controlled trial. Mao Y; Chen L; He T; Li J; Zou A; Li F; Chen F; Fan B; Ni W; Xiao W; You H; Fu W BMJ Open; 2022 Jul; 12(7):e059186. PubMed ID: 35803624 [TBL] [Abstract][Full Text] [Related]
20. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. Altenburg J; de Graaff CS; Stienstra Y; Sloos JH; van Haren EH; Koppers RJ; van der Werf TS; Boersma WG JAMA; 2013 Mar; 309(12):1251-9. PubMed ID: 23532241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]